FRANCISCO JOSÉ TINAHONES MADUEÑO – ENSAYO CLÍNICO CON MEDICAMENTOS – NOVO NORDISK A/S
The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease
by prodriguez | Jul 3, 2024 | Clinical Trials, Ensayos Clínicos - A-02 | 0 comments